Crinetics Pharmaceuticals Inc (CRNX) is now in the Fair zone, suggesting that its current forward PS ratio of 129.59 is considered Fairly compared with the five-year average of -8.20. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between 24.55 to 93.98 according to relative valuation method.

Relative Value

Fair Zone

24.55-93.98

Current Price：40.68

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Crinetics Pharmaceuticals Inc (CRNX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Crinetics Pharmaceuticals Inc (CRNX) has a current Price-to-Book (P/B) ratio of 4.12. Compared to its 3-year average P/B ratio of 3.92, the current P/B ratio is approximately 5.09% higher. Relative to its 5-year average P/B ratio of 3.72, the current P/B ratio is about 10.77% higher. Crinetics Pharmaceuticals Inc (CRNX) has a Forward Free Cash Flow (FCF) yield of approximately -7.98%. Compared to its 3-year average FCF yield of -8.35%, the current FCF yield is approximately -4.37% lower. Relative to its 5-year average FCF yield of -8.85%, the current FCF yield is about -9.75% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CRNX competitors is 23.45, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX.O) exhibits a P/S ratio of 129.59, which is 452.72% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CRNX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CRNX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CRNX currently overvalued or undervalued?

What is Crinetics Pharmaceuticals Inc (CRNX) fair value?

CRNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between 24.55 to 93.98 according to relative valuation method.

How does CRNX's valuation metrics compare to the industry average?

The average P/S ratio for CRNX's competitors is 23.45, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX) exhibits a P/S ratio of 129.59, which is 452.72% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Mar 02 2026?

As of Mar 02 2026, Crinetics Pharmaceuticals Inc (CRNX) has a P/B ratio of 4.12. This indicates that the market values CRNX at 4.12 times its book value.

What is the current FCF Yield for Crinetics Pharmaceuticals Inc (CRNX) as of Mar 02 2026?

As of Mar 02 2026, Crinetics Pharmaceuticals Inc (CRNX) has a FCF Yield of -7.98%. This means that for every dollar of Crinetics Pharmaceuticals Inc's market capitalization, the company generates -7.98 cents in free cash flow.

What is the current Forward P/E ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Mar 02 2026?

As of Mar 02 2026, Crinetics Pharmaceuticals Inc (CRNX) has a Forward P/E ratio of -8.36. This means the market is willing to pay $-8.36 for every dollar of Crinetics Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Mar 02 2026?

As of Mar 02 2026, Crinetics Pharmaceuticals Inc (CRNX) has a Forward P/S ratio of 129.59. This means the market is valuing CRNX at $129.59 for every dollar of expected revenue over the next 12 months.

CRNX Valuation